Ginkgo Bioworks Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $625.29M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $20.00M | $-0.75 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $19.00M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | $33.00M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $39.00M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $50.00M | $-1.10 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $48.32M | $-1.68 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | After market close | $44.00M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $89.00M | $-1.08 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total cash burnnon-GAAP | 2026 | -$150.00M to -$125.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ginkgo Bioworks filed with the SEC
Ginkgo Bioworks Reports Second Quarter 2026 Results, Wins Government Contracts to Build Autonomous Labs at MIT, Caltech, Northwestern, and University of Maryland
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Announces Date of Second Quarter 2026 Results Presentation
Regulation FD disclosure · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Second Quarter 2024 Financial Results
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K/A
Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports First Quarter 2024 Financial Results
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks and Google Cloud Partner to Build Next Generation AI Platform for Biological Engineering and Biosecurity
Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports First Quarter 2023 Financial Results
Results of operations · EX-99 to Form 8-K
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Interim Periods Ended September 30, 2022 and September 30, 2021
Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.2 to Form 8-K
Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review
Results of operations · EX-99.1 to Form 8-K
Item 14. Other Expenses of Issuance and Distribution
Other events · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Completes Acquisition of Zymergen
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Acquisition is expected to accelerate the development of Ginkgo’s innovative horizontal synthetic biology
Material agreement · Other events · EX-99.1 to Form 8-K
Ginkgo and Bayer Sign Definitive Agreement to Build Agricultural Biologicals R&D Platform Capabilities
Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ginkgo Bioworks Provides Preliminary Unaudited 2021 Revenue Highlights and Business Review
Results of operations · EX-99.1 to Form 8-K
GINKGO BIOWORKS, INC. AND SUBSIDIARIES
Other events · EX-99.1 to Form 8-K
Ginkgo Bioworks Reports Third Quarter 2021 Results
Results of operations · EX-99.1 to Form 8-K